The development of a novel transcatheter arterial infusion chemotherapy and significance of combination with molecular targeted agents

我们设计了一种新的经导管动脉插管化疗，用于肝细胞癌的血管内治疗，不使用固体栓塞剂，使用碘油和可降解淀粉微球(DSM)。我们在临床试验中观察了顺铂的疗效。在这项研究中，我们检验了这种新的肝动脉插管化疗的有效性，这种新的肝动脉插管化疗使用米铂与碘油的亲和力比顺铂更好。2011年，我们开始了一项前瞻性随机研究，分两组(DSM非联合组、DSM联合组)。到目前为止，我们治疗了30例。目前，DSM联合组无进展生存期有延长趋势，有效率较高。我们认为这种治疗作为一种新的肝动脉插管化疗是有用的。

We designed a novel transcatheter arterial infusion chemotherapy as transvascular treatment for hepatocellular carcinoma, without the use of a solid embolic material, and the use of lipiodol and degradable starch microspheres (DSM). We investigated the efficancy of this therapy using cisplatin in clinical trial. In this study, we examined the usefulness of this new hepatic arterial infusion chemotherapy using miriplatin affinity with lipiodol better than cisplatin. In 2011, we start a prospective randomized study by two groups (DSM non-combination group, DSM combination group). So far, we treated in 30 cases. At the moment, progression-free survival tend to extended in DSM combination group, andresponse rate to be high in DSM combination group. We think this treatment is useful as a new hepatic arterial infusion chemotherapy.